Article
Immunology
Cecilia L. Llave, Maria Esterlita V. Uy, Hilton Y. Lam, Josephine G. Aldaba, Clarence C. Yacapin, Michelle B. Miranda, Haidee A. Valverde, Wilda T. Silva, Saira Nawaz, Rose C. Slavkovsky, Jessica Mooney, Elisabeth L. Vodicka
Summary: Cervical cancer is the second most common cancer among women in the Philippines. HPV vaccines provide protection against the most common cancer-causing HPV types. This study analyzed the cost-effectiveness of different HPV vaccine products and found that some vaccines were cost-effective from both government and societal perspectives, while GARDASIL (R) 9 was not cost-effective under any scenario.
Article
Pharmacology & Pharmacy
Steven Simoens, Andre Bento-Abreu, Barbara Merckx, Sophie Joubert, Steve Vermeersch, Andrew Pavelyev, Stefan Varga, Edith Morais
Summary: Expanding HPV vaccination programs in Belgium to gender-neutral vaccination (GNV) with the 9-valent HPV vaccine can reduce the burden of HPV-related disease and deaths, and is cost-effective compared to female-only vaccination (FOV).
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Tsuyoshi Okuhara, Hiroko Okada, Eiko Goto, Aiko Tsunezumi, Yumi Kagawa, Takahiro Kiuchi
Summary: This study examined the effects of messages targeting the fundamental human motives of kin care and disease avoidance on HPV vaccination intentions among mothers with daughters. The results showed that intervention messages based on these motives significantly increased vaccination intentions compared to a control message. The evolutionary theoretical approach may have the potential to enhance communication strategies for HPV vaccination recommendations.
Article
Immunology
Motoko Tanaka, Reiko Okubo, Shu-Ling Hoshi, Nobuyuki Ishikawa, Masahide Kondo
Summary: The study showed that adding a fifth dose of DTaP vaccine for 6-year-old children in Japan is not cost-effective in terms of achieving herd immunity among unvaccinated infants. The duration of pertussis disease and the incidence rate of pertussis were significant factors impacting the ICER. When the disease burden of pertussis decreased, the booster strategy resulted in fewer QALYs gained and greater costs compared with the no booster strategy.
Article
Biotechnology & Applied Microbiology
Renata Linertova, Carmen Guirado-Fuentes, Javier Mar-Medina, Conor Teljeur
Summary: This study estimated the costs and benefits of HPV vaccination in Spain, comparing two types of vaccine, only in girls or in both genders. The analysis considered both direct and indirect protection provided by vaccination. The results suggest that vaccinating all adolescents may not be cost-effective, but including protection against additional cancers or reducing the vaccine price would make it worth vaccinating all adolescents in Spain. The study also highlighted ethical arguments supporting HPV vaccination for both genders.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Dean Langsam, Dor Kahana, Erez Shmueli, Dan Yamin
Summary: The study suggests that adjusting the vaccination schedule can reduce pertussis incidence and healthcare visits, increasing maternal vaccination coverage is cost-effective, while the contribution of the second booster dose is limited.
Article
Immunology
Risa Kudo, Masayuki Sekine, Manako Yamaguchi, Megumi Hara, Sharon J. B. Hanley, Yutaka Ueda, Asami Yagi, Sosuke Adachi, Megumi Kurosawa, Etsuko Miyagi, Takayuki Enomoto
Summary: The study revealed that Japanese girls have poor knowledge about cervical cancer screening, HPV, and HPV vaccines, with the unvaccinated group having particularly low awareness and engaging in higher sexual activity. Only a very small percentage of girls experienced changes in awareness about sexual activity after vaccination. This highlights the importance of providing information about vaccine effectiveness and the benefits of cancer screening, especially for unvaccinated girls.
Article
Medicine, General & Internal
Horace C. W. Choi, Kathy Leung, Karen K. L. Chan, Yuan Bai, Mark Jit, Joseph T. T. Wu
Summary: This study aimed to evaluate the cost-effectiveness of determining the optimal screening strategies for vaccinated and unvaccinated cohorts. It found that HPV testing is a cost-effective alternative to cytology for vaccinated cohorts, and the optimal screening frequency depends on vaccine uptake.
Article
Multidisciplinary Sciences
Krishna P. Reddy, Kieran P. Fitzmaurice, Justine A. Scott, Guy Harling, Richard J. Lessells, Christopher Panella, Fatma M. Shebl, Kenneth A. Freedberg, Mark J. Siedner
Summary: Cost, supply, and logistics are challenges for COVID-19 vaccine rollout in low and middle-income countries. Modeling a vaccination program in South Africa, the study demonstrates the importance of a rapid vaccine rollout in preventing infections and deaths, even with moderately efficacious vaccines. Implementing prompt vaccination procurement, distribution, and rollout could provide high value and decrease both deaths and healthcare costs across a wide range of assumptions.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Ikponmwosa Osaghae, Charles Darkoh, Onyema Greg Chido-Amajuoyi, Wenyaw Chan, Paige Padgett Wermuth, Mala Pande, Sonia A. Cunningham, Sanjay Shete
Summary: This study aimed to determine the association between healthcare providers' self-efficacy in HPV vaccination hesitancy counseling and HPV vaccination acceptance. The results showed that healthcare providers with higher self-efficacy observed higher HPV vaccination acceptance after initial and follow-up counseling sessions. Therefore, healthcare providers should receive training in HPV vaccination counseling and utilize every visit to counsel hesitant patients.
Article
Medicine, General & Internal
Jane J. Kim, Kate T. Simms, James Killen, Megan A. Smith, Emily A. Burger, Stephen Sy, Catherine Regan, Karen Canfell
Summary: The study evaluated the cost-effectiveness of extending the upper age limit of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice. The findings from two independent models suggest that HPV vaccination beyond age 26 years is not cost-effective at current prices, even under a range of sensitivity analyses and favorable assumptions regarding HPV vaccination effectiveness and costs.
Letter
Biotechnology & Applied Microbiology
Mugen Ujiie, Taito Kitano, Shinya Tsuzuki
Summary: Despite the suspension of the HPV vaccine recommendation by the Japanese Ministry of Health, there has been a significant increase in the number of vaccines delivered to healthcare facilities, likely due to government efforts to convey information about the HPV vaccination and ongoing local educational programs. The incidence of reported adverse events per vaccine dose has not increased since 2016.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Public, Environmental & Occupational Health
Huixuan Zhou, Ningxin Ding, Xueyan Han, Hanyue Zhang, Zeting Liu, Xiao Jia, Jingjing Yu, Wei Zhang
Summary: This study evaluates the cost-effectiveness of the current COVID-19 vaccination strategy among the general population in mainland China. The findings show that vaccination reduces infection and death rates, saves healthcare costs, and is considered a cost-effective strategy.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Immunology
Arnold Hagens, Ahmet Cagkan Inkaya, Kasirga Yildirak, Mesut Sancar, Jurjen van der Schans, Aylin Acar Sancar, Serhat Unal, Maarten Postma, Selen Yegenoglu
Summary: The study indicates that COVID-19 vaccination in Turkey is highly cost-effective or even cost-saving from both healthcare and societal perspectives. The minimum required vaccine uptake for cost-effectiveness is at least 30%, with sensitivity and scenario analyses showing robust results.
Article
Immunology
Coralei E. Neighbors, Evan R. Myers, Nayani P. Weerasinghe, Gaya B. Wijayaratne, Champica K. Bodinayake, Ajith Nagahawatte, L. Gayani Tillekeratne, Christopher W. Woods
Summary: Influenza vaccination is cost-effective for the Sri Lankan population, reducing cases, hospitalizations, and deaths caused by influenza. The most influential factors are vaccine coverage and effectiveness in different age groups. Providing influenza vaccines is highly cost-effective compared to not vaccinating. However, more large-scale national studies are needed to improve data and assess the impact of vaccination implementation.